drugset / Trial / NCT00191555

Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment

NCT00191555

Phase 4 Completed 360 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to demonstrate that there is a benefit in switching chronic schizophrenic patients from conventional antipsychotic to olanzapine in terms of efficacy, neurological safety and patient's outcome.

Timeline

Start
2003-08
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Haloperidol Other / unclassified Oral
Subject Olanzapine Small molecule Oral

Indications